ArticleBiochemia medica2017
Establishing the upper reference limit of Galectin-3 in healthy blood donors.
Article in Biochemia medica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Myocardial fibrosis and viability: the role of imaging and biomarkers in patients with chronic total occlusion on coronary angiography.Biochemia medica · 2026Review
- Blood Biomarkers as a Non-Invasive Method for the Assessment of the State of the Fontan Circulation.Journal of clinical medicine · 2025Review
- Circulating Gal-3 and sST2 are associated with acute exercise-induced sustained endothelial activation: Possible relevance for fibrosis development?Experimental physiology · 2023Article
- The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand?International journal of molecular sciences · 2023Review
- Changes in plasma IRAK-M in patients with prediabetes and its relationship with related metabolic indexes: a cross-sectional study.The Journal of international medical research · 2022Article
- Impact of diabetes mellitus on outcomes of patients with sepsis: an updated systematic review and meta-analysis.Diabetology & metabolic syndrome · 2022Review
- Serum Vitamin D as a Biomarker in Autoimmune, Psychiatric and Neurodegenerative Diseases.Diagnostics (Basel, Switzerland) · 2022Review
- Bilirubin ameliorates murine atherosclerosis through inhibiting cholesterol synthesis and reshaping the immune system.Journal of translational medicine · 2022Article
- Influence of lipid-lowering drugs on inflammation: what is yet to be done?Archives of medical science : AMS · 2022Article
- Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer's Disease.Diagnostics (Basel, Switzerland) · 2021Article
- Phospholipase A2 group IIA correlates with circulating high-density lipoprotein cholesterol and modulates cholesterol efflux possibly through regulation of PPAR-γ/LXR-α/ABCA1 in macrophages.Journal of translational medicine · 2021Article
- Docking protein 1 and free fatty acids are associated with insulin resistance in patients with type 2 diabetes mellitus.The Journal of international medical research · 2021Article
- COVID-19 and Alzheimer's Disease.Brain sciences · 2021Review
- Article
- Association of Aldehyde Dehydrogenase 2 Gene Polymorphism with Myocardial Infarction.Journal of inflammation research · 2021Article
- Galectin-3 in Cardiovascular Diseases.International journal of molecular sciences · 2020Review
- Establishment of thromboelastography reference intervals by indirect method and relevant factor analyses.Journal of clinical laboratory analysis · 2020Article
- Emergency department routine data and the diagnosis of acute ischemic heart disease in patients with atypical chest pain.PloS one · 2020Article
- Galectin-3 in Acute Myocardial Infarction Patients with Atrial Fibrillation.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGalectin-3 (Gal-3) is an independent predictor of poor outcomes and mortality in patients with heart failure (HF). Thus, it has been proposed as a reliable prognostic biomarker for HF. The definition of reference intervals is mandatory for interpreting the findings of experimental studies and encouraging the routine use of biomarkers in clinical practice. To date, no study assessed the reference intervals of Gal-3 and identified the biological variables that affect its concentration in a well-defined healthy population. The aim of this study was to determine the upper reference limit (URL) of Gal-3 in a highly reliable population of healthy subjects. MATERIALS AND
methodsWe recruited 714 blood donors. After measuring surrogate biomarkers to identify underlying diseases, 8 subjects were excluded. A final population of 706 individuals (385 men (54.5%); median age 39 (18-65) years) was included. The URL was calculated using the non-parametric percentile approach.
resultsThe 97.5th percentile URL of plasma Gal-3 in our study population (90% CI) was 26.1 (23.3-31.5) ng/mL. After stratifying subjects according to age, the URL of Gal-3 was found to be considerably higher in older (> 45 years) than in younger subjects (31.5 (26.2-51.4) vs 21.8 (21-26.1) ng/mL, respectively). No sex-related differences were found in Gal-3 plasma concentration.
conclusionsWe established the URL of Gal-3 in a highly selected healthy population. Our findings indicate that age is an important determinant of Gal-3 plasma concentration, so that multiple diagnostic cut-offs should be preferably used according to the different age classes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.